• A small-molecule inhibitor that is selective for the kinase domain of the type 1 TGF-β receptor
    • Currently in phase 2 clinical trials for gliomas, pancreatic cancer, HCC, and myelodysplastic syndromes
    • Recommended dose: 150 mg PO b.i.d., 14 days on, 14 days off
    • Half-life: 6.5 hours
    • Common side effects: Neutropenia, anemia, fatigue
    (Calvo-Aller et al., 2008; Rodon Ahnert et al., 2011)
    Other topics in Targeted and Immunotherapy Agents